Posttraumatic stress disorder is a trauma- and stressor-related disorder that follows exposure to actual or threatened death, serious injury, or sexual violence and is defined by intrusion symptoms, avoidance, negative alterations in cognition and mood, and marked changes in arousal and reactivity. DSM-5-TR places PTSD outside the anxiety disorders chapter, recognizing the heterogeneity of the syndrome and the centrality of the traumatic event to its phenomenology. Lifetime prevalence in the United States is roughly 6-9%, with women affected at about twice the rate of men, and the disorder carries a heavy comorbidity burden — depression, substance use disorders, and suicidality in particular. Trauma-focused psychotherapies, especially prolonged exposure, cognitive processing therapy, and EMDR, are the highest-tier interventions; SSRIs and venlafaxine are the most evidence-supported pharmacotherapies, and prazosin retains a role for trauma-related nightmares. The clinical bottom line: a careful trauma history, a validated assessment instrument, and early referral for trauma-focused therapy will outperform most pharmacologic-only strategies.

This article was prepared on 2026-05-10 by drawing on DSM-5-TR diagnostic text, the 2023 VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder, the 2018 NICE guideline (NG116) on PTSD, the APA 2017 Clinical Practice Guideline for the Treatment of PTSD in Adults, the International Society for Traumatic Stress Studies (ISTSS) 2019 prevention and treatment guidelines, recent Cochrane systematic reviews of psychological and pharmacological interventions, and chapters from Kaplan and Sadock's Synopsis of Psychiatry (12th ed.) and Stahl's Essential Psychopharmacology (5th ed.). Search terms across PubMed and the Cochrane Library included "posttraumatic stress disorder," "trauma-focused cognitive behavioral therapy," "prolonged exposure," "cognitive processing therapy," "EMDR," "prazosin nightmares," "SSRI PTSD," and "MDMA-assisted psychotherapy." Pediatric, perinatal, and complex PTSD literature were included; primary case reports were excluded except where they illustrate a specific safety signal.

PTSD is common in trauma-exposed populations but only a minority of those exposed to a Criterion A event develop the full disorder. Conditional risk varies by trauma type, with interpersonal violence — combat, sexual assault, captivity — carrying the highest probability of PTSD onset.^1-2

Prevalence

• Lifetime prevalence in U.S. adults is approximately 6.1-8.3% in the National Comorbidity Survey Replication and the National Epidemiologic Survey on Alcohol and Related Conditions-III.^1-2
• 12-month prevalence is approximately 3.5-4.7% in U.S. community samples.^1-2
• Conditional risk after Criterion A trauma exposure is roughly 10-20% overall, but climbs above 30-50% after rape, captivity, or genocide-related trauma.¹

Demographics

• Female-to-male ratio is approximately 2:1 across most populations, partly attributable to the differential distribution of trauma types and partly to sex-related differences in HPA axis and fear-extinction biology.^1,3
• Median age of onset is in the third decade, but onset can occur at any age following exposure; childhood-onset cases tend toward chronicity.¹
• Higher rates are observed in U.S. veterans of the Vietnam, Iraq, and Afghanistan conflicts, with 12-month prevalence in OEF/OIF/OND veterans reported between 13% and 20%.⁴

Comorbidity

• More than 80% of individuals with lifetime PTSD meet criteria for at least one other psychiatric disorder.¹
• The most frequent comorbidities are Major depressive disorder (about 50%), Alcohol use disorder (about 30-50% in men), other substance use disorders, generalized anxiety disorder, and panic disorder.^1-2
• Suicidal ideation, attempts, and completed suicide are markedly elevated; PTSD roughly doubles the odds of suicide attempt independent of comorbid depression.⁵

Risk factors

• Pre-traumatic: female sex, prior trauma exposure, childhood adversity, lower socioeconomic status, prior psychiatric history, and family history of psychiatric illness.^1,3
• Peri-traumatic: trauma severity, perceived life threat, peritraumatic dissociation, and physical injury.³
• Post-traumatic: lack of social support, additional life stressors, and ongoing trauma reminders are among the strongest modifiable predictors of chronicity.³

PTSD is best framed as a disorder of fear learning, threat appraisal, and memory consolidation rather than a unitary lesion. Convergent evidence implicates a hyperresponsive amygdala, a hypoactive ventromedial prefrontal cortex, and a hippocampus that fails to contextualize threat, embedded in broader disruption of Default mode network and Salience network connectivity.^6-7

Neurocircuitry

• Amygdala hyperreactivity to threat cues, including subliminal stimuli, is among the most replicated functional MRI findings in PTSD.⁶
• The Ventromedial prefrontal cortex shows blunted activation and reduced top-down inhibition of the amygdala, mapping onto impaired Fear extinction recall.^6-7
• Hippocampal volume is reduced on average in PTSD, a finding present in twin studies even in the unaffected co-twin, suggesting a pre-existing vulnerability marker rather than a purely acquired lesion.⁸
• Salience and default mode network alterations contribute to intrusive re-experiencing, hypervigilance, and rumination.⁷

Neurochemistry

• Sustained noradrenergic hyperactivity, particularly via the locus coeruleus, drives hyperarousal, nightmares, and reactivity; this is the rationale for prazosin and clonidine use.⁹
• HPA axis findings are paradoxical relative to depression: many studies show low or normal cortisol with enhanced glucocorticoid receptor sensitivity and exaggerated dexamethasone suppression.¹⁰
• Glutamatergic dysregulation, particularly NMDA receptor signaling, underlies fear-memory consolidation and reconsolidation and is the target of emerging ketamine and D-cycloserine augmentation strategies.¹¹
• Endocannabinoid and opioid systems modulate fear extinction and are areas of active investigation.⁶

Genetics

• Twin studies estimate heritability at roughly 30-40% conditional on trauma exposure.¹²
• GWAS efforts (Psychiatric Genomics Consortium PTSD workgroup) have identified genome-wide-significant loci that overlap substantially with major depressive disorder and neuroticism, consistent with shared internalizing liability.¹²
• FKBP5 polymorphisms interacting with childhood trauma are among the most replicated gene-environment findings, plausibly via altered glucocorticoid receptor sensitivity.^10,12

Integrative model

• The current working model integrates a fear-conditioning framework (Pavlovian acquisition, failure of extinction, generalization) with disordered episodic memory consolidation, persistent threat appraisal, and avoidance-driven maintenance — each of which maps onto a different therapeutic target (exposure, cognitive restructuring, pharmacologic dampening of arousal).^6-7

DSM-5-TR places PTSD within Trauma- and Stressor-Related Disorders (chapter introduced in DSM-5) and requires direct or indirect exposure to a qualifying event followed by symptoms across four clusters lasting more than one month and producing functional impairment.¹³

DSM-5-TR criteria (paraphrased)

• Criterion A — Exposure to actual or threatened death, serious injury, or sexual violence by direct experience, witnessing, learning of such an event affecting a close family member or friend, or repeated/extreme exposure to aversive details (e.g., first responders). Exposure through electronic media does not qualify unless work-related.¹³
• Criterion B — Intrusion symptoms (≥1): recurrent intrusive memories, distressing dreams related to the event, dissociative reactions including Flashbacks, intense distress to trauma cues, and physiological reactivity to cues.¹³
• Criterion C — Persistent avoidance (≥1): of internal reminders (thoughts, feelings) or external reminders (people, places, situations).¹³
• Criterion D — Negative alterations in cognitions and mood (≥2): inability to recall key features of the event (typically dissociative amnesia, not head injury), persistent negative beliefs, distorted blame of self or others, persistent negative emotions, markedly diminished interest, detachment, and inability to experience positive emotions.¹³
• Criterion E — Marked alterations in arousal and reactivity (≥2): irritable or aggressive behavior, reckless or self-destructive behavior, hypervigilance, exaggerated startle, concentration problems, and sleep disturbance.¹³
• Criterion F — Duration > 1 month.
• Criterion G — Clinically significant distress or functional impairment.
• Criterion H — Not attributable to a substance or another medical condition.

Specifiers

• With dissociative symptoms — depersonalization or derealization predominating; this subtype shows distinct neural correlates (greater medial prefrontal activation, dampened limbic reactivity) and may inform treatment selection.¹⁴
• With delayed expression — full criteria not met until at least 6 months after the event, though some symptoms typically appear earlier.¹³

Pediatric considerations

• DSM-5-TR includes a developmentally adapted PTSD criteria set for children 6 years and younger, with fewer required symptoms in clusters C and D combined and developmentally appropriate descriptors (e.g., trauma-themed play, frightening dreams without recognizable content).¹³

ICD-11 differences

• ICD-11 narrows PTSD to three core clusters: re-experiencing in the here-and-now, avoidance, and a sense of current threat. The negative cognitions and mood cluster is largely excluded from PTSD itself.¹⁵
• ICD-11 introduces Complex PTSD as a separate diagnosis, requiring all three core PTSD elements plus persistent disturbances in self-organization (affective dysregulation, negative self-concept, disturbances in relationships) typically following prolonged or repeated trauma.¹⁵
• DSM-5-TR does not include a Complex PTSD diagnosis; clinicians instead document PTSD with relevant comorbidities or specifiers.

PTSD presents heterogeneously, and the dominant cluster often shapes the clinical picture: some patients are visibly hypervigilant and reactive, others present primarily with emotional numbing, withdrawal, and depressive features. The trauma is the unifying thread, but the functional impairment often arrives via avoidance.^13,16

Symptom clusters in practice

• Intrusion: spontaneous intrusive memories, nightmares (often with veridical or symbolic trauma content), flashbacks ranging from brief sensory intrusions to full dissociative re-experiencing, and intense reactivity to cues such as helicopters, anniversaries, or specific smells.
• Avoidance: behavioral (avoiding driving after a motor vehicle accident) and cognitive (suppressing memories or feelings); avoidance is the cluster that most commonly maintains the disorder by preventing extinction learning.
• Negative cognitions and mood: pervasive guilt and shame, distorted self-blame, foreshortened future, anhedonia, and detachment. Trauma-related guilt is a strong predictor of suicidality.⁵
• Hyperarousal: exaggerated startle, sleep-onset and maintenance insomnia, irritability that may escalate to aggression, reckless behavior, and impaired concentration.

Course features

• Onset is typically within 3 months of the trauma; delayed expression occurs in roughly 25% of cases.¹
• Symptoms typically wax and wane with reminders, anniversaries, and life stressors.
• Approximately one-third recover within the first year without treatment; one-third have persistent symptoms beyond 10 years.^1,16

Red flags requiring urgent evaluation

• Active suicidal ideation, particularly with trauma-related guilt or hopelessness.
• Dissociative episodes during which the patient is at risk (driving, caring for children).
• Comorbid alcohol or sedative-hypnotic use disorder with overdose risk.
• Aggression or homicidal ideation, especially in combat veterans with traumatic brain injury comorbidity.

PTSD overlaps phenomenologically with several disorders, and the trauma history alone does not establish the diagnosis — the symptom profile and timing must align. Distinguishing PTSD from depression, panic disorder, OCD, and, increasingly, complex PTSD and borderline personality disorder is high-yield clinically and on examinations.

Psychiatric differentials

• Acute stress disorder: same symptom architecture but duration 3 days to 1 month after the trauma.¹³
• Adjustment disorder: stressor need not meet Criterion A; symptoms do not meet PTSD criteria; resolves within 6 months of stressor cessation.¹³
• Major depressive disorder: anhedonia, guilt, and concentration problems overlap, but MDD lacks intrusion symptoms tied to a trauma and Criterion A exposure.
• Panic disorder: panic attacks may occur in PTSD as cued reactions to reminders; primary panic disorder features uncued attacks and anticipatory anxiety not organized around a trauma.
• Obsessive-compulsive disorder: intrusive thoughts in OCD are ego-dystonic and not memories of a real event; compulsions are aimed at neutralizing obsessions, not trauma reminders.
• Borderline personality disorder: shares affect dysregulation, dissociation, and interpersonal disturbance; often comorbid with PTSD, particularly after childhood abuse. Complex PTSD overlaps further but spares the chronic instability of identity and relationships seen in BPD.¹⁵
• Psychotic disorders: flashbacks may be mistaken for hallucinations; trauma content, retained reality testing between episodes, and absence of formal thought disorder favor PTSD.
• Dissociative disorders: dissociative amnesia and dissociative identity disorder may co-occur; if dissociation predominates without re-experiencing or hyperarousal, consider a primary dissociative disorder.
• Traumatic brain injury: post-concussive symptoms (headache, dizziness, photophobia) and PTSD symptoms (insomnia, irritability, concentration problems) overlap; both can follow combat or motor vehicle trauma and frequently co-exist.⁴

Medical mimics and contributors

• Hyperthyroidism — anxiety, insomnia, irritability, tachycardia.
• Pheochromocytoma — paroxysmal hyperadrenergic episodes mimicking panic and hyperarousal.
• Temporal lobe epilepsy — déjà vu, autonomic phenomena, and dissociative-appearing episodes.
• Sleep apnea — fatigue, irritability, concentration problems; can also worsen nightmares.
• Substance intoxication or withdrawal — particularly alcohol, sedative-hypnotics, stimulants, and cannabis.
• Medications — corticosteroids, interferon, and stimulants can produce arousal and mood symptoms.

A focused trauma history paired with a validated instrument is the standard of care. The interviewer must convey that the patient is in control of the pacing, since premature detailed disclosure can be retraumatizing and impair the therapeutic alliance.¹⁷

Interview approach

• Screen all psychiatric patients for trauma exposure; many patients will not volunteer the history without a direct, normalized question.
• Begin with the diagnosis ("Have you ever experienced an event so frightening or horrible that...") rather than the narrative; obtain the index trauma the patient identifies as most distressing.
• Assess the four symptom clusters explicitly; patients with prominent avoidance may underreport.
• Screen for suicidality, homicidality, and substance use at the first visit.
• In military or first-responder patients, screen specifically for moral injury and traumatic brain injury.⁴

Validated rating scales

• Clinician-Administered PTSD Scale (CAPS-5): structured clinician interview, considered the diagnostic gold standard for research and forensic settings.¹⁸
• PTSD Checklist for DSM-5 (PCL-5): 20-item self-report; cutoff of 31-33 commonly used for probable PTSD; useful for screening and outcome monitoring.¹⁹
• Primary Care PTSD Screen for DSM-5 (PC-PTSD-5): 5-item screen used in VA primary care; positive at ≥3.²⁰
• Life Events Checklist (LEC-5): standardized trauma exposure inventory typically paired with CAPS or PCL.¹⁸
• Impact of Event Scale-Revised (IES-R): widely used in non-U.S. and disaster psychiatry settings.

Physical examination and laboratory workup

• Vital signs, weight, and a focused neurologic exam, including assessment for prior head injury.
• TSH, CBC, comprehensive metabolic panel, urine toxicology, and pregnancy testing in patients of childbearing potential before initiating pharmacotherapy.
• ECG when prescribing agents with QT effects (e.g., high-dose citalopram, mirtazapine in older adults with cardiac risk).
• MRI is not routinely indicated; reserve neuroimaging for atypical features, focal neurologic findings, or significant TBI history.
• EEG only if seizure activity is suspected.

Trauma-focused psychotherapies are the highest-tier interventions for PTSD across major guidelines, with pharmacotherapy a reasonable first-line alternative when evidence-based therapy is unavailable, declined, or insufficient.^21-23 The default sequence in stable adults is to offer trauma-focused therapy first, layer pharmacotherapy when indicated, and reserve neuromodulation and emerging strategies for treatment-resistant cases.

Pharmacotherapy

• First-line agents: SSRIs sertraline and paroxetine carry FDA approval for PTSD; fluoxetine has supportive evidence at similar magnitude. The SNRI venlafaxine extended-release also has strong RCT-level support and is recommended first-line in VA/DoD 2023.^21,24
• Effect sizes are modest; number-needed-to-treat estimates for SSRI/SNRI response cluster around 4-8.²⁴
• Adequate trials require 8-12 weeks at therapeutic doses (sertraline 50-200 mg, paroxetine 20-60 mg, venlafaxine XR 75-300 mg) before declaring failure.²¹
• Second-line: switching to another first-line SSRI/SNRI; mirtazapine has modest supportive evidence and may help sleep and appetite; nefazodone has evidence but limited use due to hepatotoxicity boxed warning.²⁴
• Augmentation for treatment-resistant cases: switching agents takes priority over augmentation in current guidelines, but topiramate, prazosin (for nightmares), and atypical antipsychotic augmentation have been studied with mixed results.^24-25
• Antipsychotics: risperidone and quetiapine showed inconsistent benefit in RCTs; the VA/DoD 2023 guideline recommends against routine use of risperidone and offers no recommendation for or against quetiapine, citing weak evidence and adverse-effect burden.²¹
• Prazosin: an alpha-1 antagonist with long-standing supportive evidence for trauma-related nightmares and sleep disturbance, though the large multisite PACT trial in veterans (Raskind et al., NEJM 2018) did not show benefit over placebo, leading to downgraded but retained guidance for selected patients.²⁶
• Benzodiazepines and the older agents (TCAs, MAOIs) are not recommended first-line; benzodiazepines are specifically discouraged.^21-22

Psychotherapy

• Trauma-focused cognitive behavioral therapy (TF-CBT) is the umbrella category for the highest-tier interventions and includes Prolonged exposure (PE) and Cognitive processing therapy (CPT). Both are strongly recommended by VA/DoD 2023, NICE 2018, and APA 2017.^21-23
• Prolonged exposure (Foa): typically 8-15 weekly 90-minute sessions combining imaginal exposure to the trauma memory with in vivo exposure to avoided cues; large RCT evidence in civilian and veteran populations.²⁷
• Cognitive processing therapy (Resick): 12 sessions focused on identifying and modifying trauma-related "stuck points" — distorted beliefs about safety, trust, power, esteem, and intimacy.²⁸
• Eye movement desensitization and reprocessing (EMDR): structured 8-phase protocol pairing brief recall of the trauma memory with bilateral stimulation; comparable efficacy to PE/CPT in head-to-head trials and meta-analyses; recommended first-line by NICE and ISTSS, conditionally recommended by APA.^22-23,29
• Written Exposure Therapy (Sloan): 5-session protocol with growing evidence and strong noninferiority data versus CPT.³⁰
• Brief eclectic psychotherapy and narrative exposure therapy (NET) have supporting evidence, particularly NET in refugee and post-conflict populations.²³
• Stress inoculation training, present-centered therapy, and supportive counseling have weaker evidence and are generally reserved as alternatives when trauma-focused therapy is declined or unavailable.²¹
• Group and internet-delivered formats (e.g., guided iCBT) extend access; effect sizes are smaller than individual face-to-face TF-CBT but clinically meaningful.²³

Neuromodulation

• Transcranial magnetic stimulation (TMS) protocols targeting the right or left dorsolateral prefrontal cortex have growing evidence in PTSD, including theta-burst variants; the FDA has not granted a PTSD-specific indication, and the VA/DoD 2023 guideline offers a weak recommendation for TMS in patients who have not responded to or cannot access first-line treatments.^21,31
• Stellate ganglion block has emerging but inconsistent RCT evidence and is currently considered investigational outside specialty centers.³²
• Vagus nerve stimulation, deep brain stimulation, and tDCS remain investigational.

Adjunctive

• Sleep hygiene, treatment of comorbid OSA (which worsens nightmares and arousal), and cautious management of insomnia with non-benzodiazepine agents (trazodone, ramelteon) when behavioral measures are insufficient.
• Treatment of comorbid substance use disorder: integrated care models such as Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) outperform sequential approaches.³³
• Exercise, mind-body interventions (yoga, mindfulness-based stress reduction), and peer support programs have modest supportive evidence as adjuncts but are not stand-alone treatments.²³
• Psychoeducation for the patient and, with consent, the family is recommended across all phases of care.

All effective PTSD treatments carry costs — pharmacologic adverse effects, the emotional intensity of trauma-focused work, and the burden of sustained adherence. The evidence base, while substantial, has well-recognized limitations including high dropout, modest effect sizes for medications, and underrepresentation of complex PTSD and intersectional populations.

Common harms

• SSRIs and SNRIs: sexual dysfunction, GI upset, sleep disturbance, weight changes, and discontinuation syndrome on abrupt taper.
• Venlafaxine specifically: dose-dependent hypertension and a particularly difficult discontinuation syndrome.
• Prazosin: orthostatic hypotension, first-dose syncope, nasal congestion.
• Atypical antipsychotics: metabolic syndrome, sedation, extrapyramidal symptoms, and rare neuroleptic malignant syndrome.
• Trauma-focused psychotherapies: transient symptom exacerbation early in treatment, distress related to imaginal exposure, and risk of premature dropout.^27-28

Serious or rare harms

• SSRIs/SNRIs: hyponatremia (especially in older adults), serotonin syndrome with combinations, increased bleeding risk, and an FDA boxed warning for suicidality in patients under 25.
• Benzodiazepines (when prescribed despite recommendations): tolerance, dependence, falls and fractures in older adults, respiratory depression in combination with opioids, and cognitive impairment.²¹
• TMS: rare seizure (≈0.01-0.1% per session).
• MDMA-assisted psychotherapy: cardiovascular events, hyperthermia, and concerns about therapist boundary violations raised in FDA advisory deliberations.³⁴

Monitoring and discontinuation

• Suicidality screening at every visit during initiation and dose changes.
• BP monitoring on venlafaxine, particularly at doses ≥225 mg/day.
• Sodium monitoring in older adults on SSRIs; check at baseline and within 2-4 weeks if symptoms suggest hyponatremia.
• Taper SSRIs/SNRIs over weeks to months when discontinuing; paroxetine and venlafaxine require slower tapers due to short half-life.
• Reassess every 4-12 weeks during pharmacotherapy with a validated scale (PCL-5).

Limitations of the evidence base

• Veteran and military samples dominate the U.S. trial literature; generalizability to civilian, refugee, and complex-trauma populations is incomplete.²¹
• Most trials are 8-16 weeks; long-term efficacy and relapse data are sparse.
• Head-to-head pharmacotherapy trials are limited; class effect of SSRIs/SNRIs is inferred more than established.
• Publication bias and industry sponsorship affect older pharmacotherapy literature.
• Complex PTSD as defined in ICD-11 lacks a robust treatment evidence base separate from PTSD trials.¹⁵

PTSD presentation, treatment selection, and risk profile shift meaningfully across the lifespan and across populations defined by exposure type. Tailoring care to these contexts is a core competency.

Pediatric

• DSM-5-TR provides a developmentally adapted criteria set for children 6 years and younger; for older children and adolescents the adult criteria apply.¹³
• Trauma-Focused CBT (Cohen, Mannarino, Deblinger) is the strongest-evidence pediatric PTSD treatment, including a caregiver component when developmentally appropriate.³⁵
• SSRIs lack pediatric PTSD-specific FDA approval; pharmacotherapy is generally reserved for refractory cases or significant comorbid depression, with informed-consent discussion of the boxed warning for suicidality.

Geriatric

• Late-onset and reactivated PTSD occur, often with retirement, bereavement, medical illness, or cognitive decline removing protective avoidance strategies.
• Pharmacotherapy choice favors agents with lower anticholinergic and orthostatic burden; mirtazapine and SSRIs (sertraline, escitalopram) are commonly preferred over paroxetine and TCAs.
• Hyponatremia, falls, and bleeding risk are amplified.

Perinatal

• Sertraline is generally preferred in pregnancy and lactation given the largest safety dataset; treatment of moderate-to-severe PTSD in pregnancy generally outweighs risks of untreated illness.³⁶
• Trauma-focused psychotherapy is often the preferred first-line modality in pregnancy and the postpartum period.
• Birth trauma is increasingly recognized as a Criterion A trigger and warrants specific screening.

Comorbid medical illness

• Patients post-MI, stroke, ICU stay, or cancer treatment have elevated PTSD rates; routine screening in these populations improves detection.³⁷
• Drug interactions with cardiac medications (e.g., paroxetine and tamoxifen via CYP2D6) influence agent selection.

Comorbid substance use

• Integrated, concurrent treatment outperforms sequential models; COPE (Concurrent Treatment of PTSD and SUD Using Prolonged Exposure) is the best-studied protocol.³³
• Avoid prescribing benzodiazepines or stimulants in patients with active SUD whenever possible.

Cultural and refugee considerations

• Idioms of distress vary; somatic presentations (chronic pain, GI symptoms) may dominate.
• Narrative Exposure Therapy was developed for and has the strongest evidence in refugee and post-conflict populations.²³
• Interpreters trained in trauma work, awareness of host-country immigration stressors, and ongoing safety threats meaningfully alter treatment planning.

PTSD is a treatable but often chronic disorder. With evidence-based care, a substantial minority achieve remission, but residual symptoms and relapse with stressors are common.

Natural history

• Approximately one-third of cases remit within the first year without treatment; another third have a chronic course beyond 10 years.^1,16
• Chronicity is more likely with childhood-onset, multiple traumas, comorbid depression or SUD, ongoing trauma reminders, and lack of social support.³

Treatment response

• Trauma-focused psychotherapy produces clinically meaningful symptom reduction in roughly 50-70% of completers, with loss of diagnosis in 40-60% across studies.^27-29
• SSRI/SNRI response rates (≥30% CAPS reduction) are roughly 50-60%, with remission rates of 20-30%.²⁴
• Combined pharmacotherapy and trauma-focused psychotherapy has not consistently shown superiority over psychotherapy alone, though it remains common practice.²¹

Mortality

• PTSD is associated with increased all-cause mortality, driven primarily by suicide, cardiovascular disease, and unintentional injury.^5,38
• Suicide risk is elevated roughly 2-fold to 4-fold compared with the general population, with veterans and survivors of interpersonal violence at particular risk.⁵

Functional outcomes

• Persistent occupational impairment, reduced quality of life, and relationship dysfunction are common even in symptomatic responders.
• Early evidence-based intervention is associated with better long-term function and lower healthcare utilization.¹⁶

PTSD-related emergencies most often involve suicidality, severe dissociation, agitation, or acute substance use complications. Acute stabilization should not delay introduction of evidence-based longitudinal care.

Hospitalization criteria

• Active suicidal or homicidal ideation with plan or intent.
• Severe self-neglect or inability to maintain basic safety.
• Acute psychotic features or severe dissociation that places the patient at imminent risk.
• Need for monitored detoxification when comorbid SUD is unsafe to manage outpatient.

Suicide risk markers in PTSD

• Prior suicide attempt — the strongest single predictor.⁵
• Comorbid major depressive disorder, alcohol use disorder, and chronic pain.
• Trauma-related guilt and shame, hopelessness, and perceived burdensomeness.
• Access to firearms — particularly relevant in veteran populations; means-restriction counseling is a high-yield intervention.²¹

Acute agitation management

• De-escalation, environmental control, and addressing trauma-relevant triggers (close-quarters restraint, sudden physical contact) are first-line.
• Pharmacologic adjuncts when needed: oral or IM second-generation antipsychotics (e.g., olanzapine, ziprasidone) are typically preferred; benzodiazepines should be used cautiously and not as a sole agent given paradoxical disinhibition risk.

Several active debates shape current practice and will influence trainees' careers. The most consequential involve the classification of complex PTSD, the regulatory status of MDMA-assisted psychotherapy, and the role of pharmacotherapy relative to trauma-focused work.

Complex PTSD as a separate diagnosis

• ICD-11 recognizes Complex PTSD as distinct; DSM-5-TR does not. Clinicians caring for patients with prolonged or developmental trauma must navigate this gap, and ongoing trial work is examining whether ICD-11 CPTSD identifies a population with different treatment needs.¹⁵

MDMA-assisted psychotherapy

• The MAPP1 and MAPP2 phase 3 trials reported large effects on CAPS-5 versus placebo with therapy.³⁴
• In August 2024 the FDA declined approval, citing concerns about study blinding, functional unblinding, expectancy effects, and reports of therapist misconduct in the trials.
• The drug remains investigational; clinicians should counsel patients away from underground use, given cardiovascular and sexual-safety risks documented in advisory deliberations.

Prazosin for nightmares

• Earlier small RCTs supported efficacy; the large multisite PACT trial (Raskind et al., NEJM 2018) was negative overall, though subgroup analyses suggested benefit in patients with elevated standing BP.²⁶
• Guidelines now offer mixed and weakened recommendations; many clinicians continue prazosin trials in selected patients with severe nightmares.

Cannabis and cannabinoids

• Many patients self-medicate with cannabis; high-quality RCT evidence for cannabis or nabilone in PTSD is limited and inconsistent, and chronic cannabis use is associated with worsened PTSD course in observational data.³⁹
• VA/DoD 2023 recommends against cannabis or cannabinoids for PTSD outside of research settings.²¹

Critical incident stress debriefing

• Single-session psychological debriefing in the immediate post-trauma period is not recommended; multiple trials and meta-analyses suggest no benefit and possible harm in some samples.²²
• Stepped-care models with watchful waiting and symptom-targeted intervention are preferred.

Pharmacotherapy for prevention

• Hydrocortisone and propranolol have been studied for secondary prevention of PTSD after acute trauma; evidence is mixed and not strong enough to support routine use.⁴⁰

• DSM-5-TR places PTSD within Trauma- and Stressor-Related Disorders, not the anxiety disorders chapter.
• Criterion A requires actual or threatened death, serious injury, or sexual violence; vicarious exposure via electronic media (non-occupational) does not qualify.
• The four DSM-5-TR PTSD symptom clusters are intrusion (B), avoidance (C), negative cognitions and mood (D), and arousal and reactivity (E); duration must exceed one month.
• DSM-5-TR specifiers include with dissociative symptoms and with delayed expression (full criteria not met until ≥6 months post-trauma).
• ICD-11 uses three core symptom clusters and introduces Complex PTSD as a separate diagnosis; DSM-5-TR does not include Complex PTSD.
• Lifetime prevalence in U.S. adults is approximately 6-9%, with a roughly 2:1 female-to-male ratio.
• Sertraline and paroxetine are the only FDA-approved medications for PTSD; venlafaxine XR is a first-line off-label option supported by major guidelines.
• Benzodiazepines are not recommended for PTSD and may worsen long-term outcomes by impairing fear-extinction learning.
• Prolonged exposure, cognitive processing therapy, and EMDR are first-line trauma-focused psychotherapies in major guidelines.
• Prazosin is an alpha-1 antagonist used for trauma-related nightmares; the large PACT trial in 2018 was negative, leading to weakened but retained guidance.
• Single-session psychological debriefing immediately after trauma is not recommended and may be harmful.
• Hippocampal volume is reduced on average in PTSD; twin studies suggest a pre-existing vulnerability marker rather than a purely acquired lesion.
• The CAPS-5 is the diagnostic gold standard for research; the PCL-5 (cutoff 31-33) is the most-used self-report measure.
• Conditional risk for PTSD after rape or captivity exceeds 30-50%, far higher than after most non-interpersonal trauma types.
• Suicide risk in PTSD is roughly 2-4 times the general population; means-restriction counseling is a core safety intervention.

No external funding. No conflicts of interest declared. Peer-review status: pending.